Most read reports
- Eritrea: Human rights central to brighter future, says expert
- Thousands of families reunited one month after Ethiopia–Eritrea border reopens
- The Ministry of Health Eritrea launches the National Measles Rubella Vaccination and vitamin A supplementation campaign for children under 15
- Somalia and Eritrea: Security Council to Lift Sanctions on Eritrea
- Can improved Ethiopia-Eritrea relations stabilise the region?
In a high-security building in Kampala, Uganda, a man leads a group of sleuths investigating a potential killer. While they may go about their work with the meticulousness of police detectives, they are actually a different type of investigator. Professor Moses Joloba, Director of Uganda's Supranational Reference Laboratory, leads his team to pursue TB – the world’s leading killer among infectious diseases. The disease killed more than 1.6 million people around the world in 2017.
88 Million Bed Nets Distributed for Malaria
Geneva - The Global Fund to Fight AIDS, Tuberculosis and Malaria today announced that 2.3 million people living with HIV have been reached with lifesaving antiretroviral (ARV) treatment through AIDS programs it supports, a 31 per cent increase over results reported a year ago.
Global Fund-supported tuberculosis programs have so far put more than 5.4 million people on effective TB drugs treatment. Tuberculosis is the leading cause of death among HIV-infected people; the World Health Organization estimates that TB accounts for up to a …
This fact sheet outlines the principles and approach in determining the number of people on antiretroviral drugs (ARVs) for HIV/AIDS treatment, with a breakdown of the results by country, and answers to commonly-asked questions.
Question 1: How many people are receiving ARVs from programs supported by Global Fund grants?
As of June 1st 2009, programs supported by the Global Fund have reported 2.3 million people currently on ARVs for treatment of HIV/AIDS.
Question 2: What is the regional breakdown of people currently receiving ARVs?